Earlier detection of recurrent prostate cancer sooner. Choline C-11 PET scan can help doctors detect recurrent prostate cancer before it may be detected by more-conventional imaging tests.
In men with rising prostate-specific antigen (PSA) levels, this test may help detect sites of possible recurrent prostate cancer at PSA levels as low as 2 nanograms per milliliter (ng/mL). Conventional tests may not detect a recurrence until PSA levels are greater than 20 ng/mL. This could mean detecting sites of cancer recurrence months or years in advance.
- FDA-approved Choline C-11 PET scan site. Mayo Clinic's campus in Rochester, Minnesota, is the first, and currently the only, medical center in the United States to receive approval by the Food and Drug Administration (FDA) to prepare and administer the Choline C-11 PET scan imaging agent (Choline C-11 Injection). Mayo Clinic in Rochester is currently the only site in the United States using the FDA-approved imaging agent.
- Helps identify areas of active recurrent prostate cancer after all forms of treatment. Previous treatment may leave scar tissue that can be confused with active cancer when viewed using conventional imaging. Choline C-11 PET scan can help doctors distinguish between scar tissue, inactive cancer cells and active, recurrent prostate cancer.
- Team approach. At Mayo Clinic, an expert team of urologists, medical oncologists, radiation oncologists and other specialists, if needed, work together to provide the best care possible. Mayo Clinic specialists have extensive experience treating men with complex cases of recurrent prostate cancer.
- Full range of treatments available. If Mayo Clinic doctors diagnose recurrent prostate cancer, you have many treatment options. These options may include radiation therapy, including highly focused stereotactic body radiation therapy, intensity-modulated radiation therapy and brachytherapy; hormone therapy; immunotherapy; surgery to remove the prostate (prostatectomy) and, if necessary, pelvic lymph nodes; cryosurgery; and chemotherapy.
- Comprehensive cancer center. Mayo Clinic Cancer Center meets strict standards for a National Cancer Institute comprehensive cancer center, which recognizes scientific excellence and a multidisciplinary approach to cancer prevention, diagnosis and treatment.
Mayo Clinic in Rochester, Minn., Mayo Clinic in Jacksonville, Fla., and Mayo Clinic in Scottsdale, Ariz., are ranked among the Best Hospitals for cancer by U.S. News & World Report.
Aug. 05, 2014
- FDA approves production of imaging agent that helps detect prostate cancer. U.S. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm319201.htm. Accessed April 15, 2014.
- Choline C-11 injection (prescribing information). Rochester, Minn. Mayo Clinic PET Radiochemistry Facility; 2012. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Accessed April 15, 2014.
- Prostate cancer. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed April 15, 2014.
- Murphy RC, et al. The utility of 11C-Choline PET/CT for imaging prostate cancer: A pictorial guide. American Journal of Roentgenology. 2011;196:1390.
- Fuccio C, et al. Choline PET/CT for prostate cancer: Main clinical applications. European Journal of Radiology. 2011;80:50.
- Fox JJ, et al. Molecular imaging of prostate cancer. Current Opinion in Urology. 2012;22:320.
- Kitajima K, et al. Update on positron emission tomography for imaging of prostate cancer. International Journal of Urology. 2014;21:12.
- Mitchell CR, et al. Operational characteristics of 11C-Choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. The Journal of Urology. 2013;189:1308.
- Kwon ED (expert opinion). Mayo Clinic, Rochester, Minn. April 16, 2014.